Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Aberdeen, UK

Professor Kerr completed his BSc with first class honours in Pathology in 1978, followed by MB ChB in 1981 and post-graduate training in Pathology at Edinburgh University Medical School and the Royal Infirmary of Edinburgh. He obtained a MRCPath in 1988, FRCPath in 1998 and was elected Honorary FRCP(Ed) in 2006. He has been a Consultant Pathologist in Aberdeen since 1989.

Professor Kerr has been a member of the IASLC for 16 years. He was elected to the IASLC Board of Directors for four years, 2013-2017, and is also Associate Editor for the Journal of Thoracic Oncology.

Professor Kerr is also a member of the International Mesothelioma Panel, and served as Pathology Chair for the The European Organisation for Research and Treatment of Cancer (EORTC) lung cancer group from 2006-2014. He is Pathology Chair for the ETOP Lungscape group and was a member of the panel for the 2004 and 2015 WHO lung cancer classifications. He serves on the International Pulmonary Pathology Society council and is a British Thoracic Society member.

He is currently involved in the revision of the BTS Mesothelioma guidelines and is a panel member for the revision of the The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) guidelines for molecular pathology testing in lung cancer. He is a lead author of the ESMO Consensus Guidelines on pathology and molecular biomarkers for non-small-cell lung cancer.

Throughout his career, he has worked in diagnostic histopathology with a special interest in thoracic pathology. He has had a career-long interest in lung cancer and has research interests in pulmonary pre-neoplasia and carcinogenesis, lung tumour diagnosis and classification, and in the identification of predictors of therapy response.